Skip to main content

High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.

Publication ,  Journal Article
Petersen, FB; Appelbaum, FR; Bigelow, CL; Buckner, CD; Clift, RA; Sanders, JE; Storb, R; Sullivan, KM; Weiden, PL; Fefer, A
Published in: Bone Marrow Transplant
September 1989

Twenty-four patients with advanced malignant lymphoma including Hodgkin's disease (HD, n = 1), intermediate grade non-Hodgkin's lymphoma (IGL, n = 12) and high-grade non-Hodgkin's lymphoma (HGL, n = 11) were prepared for syngeneic (n = 2), allogeneic (n = 11) or autologous (n = 11) marrow transplantation with cytosine arabinoside, 3 g/m2 every 12h for 12 doses (HDAC) and total body irradiation, 200 cGy daily for 6 days (TBI) to determine toxicity and efficacy. Eight patients (33%) died from early regimen related toxicity and all eight had a Karnofsky performance score less than or equal to 80 at the start of treatment. The actuarial probability of disease-free survival was 17% with a 65% probability of relapse at 4 years after transplantation. Four patients are surviving 2-4 years post-transplant, three transplanted for IGL and one for HD. None of the patients transplanted for HGL survived. The result of this phase II study suggests that HDAC followed by TBI and marrow infusion offers no apparent advantage over cyclophosphamide + TBI for patients with relapsed advanced malignant lymphoma. Earlier transplantation currently is the only demonstrated method of achieving better results.

Duke Scholars

Published In

Bone Marrow Transplant

ISSN

0268-3369

Publication Date

September 1989

Volume

4

Issue

5

Start / End Page

483 / 488

Location

England

Related Subject Headings

  • Whole-Body Irradiation
  • Middle Aged
  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • Immunology
  • Humans
  • Hodgkin Disease
  • Cytarabine
  • Combined Modality Therapy
  • Clinical Trials as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Petersen, F. B., Appelbaum, F. R., Bigelow, C. L., Buckner, C. D., Clift, R. A., Sanders, J. E., … Fefer, A. (1989). High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. Bone Marrow Transplant, 4(5), 483–488.
Petersen, F. B., F. R. Appelbaum, C. L. Bigelow, C. D. Buckner, R. A. Clift, J. E. Sanders, R. Storb, K. M. Sullivan, P. L. Weiden, and A. Fefer. “High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.Bone Marrow Transplant 4, no. 5 (September 1989): 483–88.
Petersen FB, Appelbaum FR, Bigelow CL, Buckner CD, Clift RA, Sanders JE, et al. High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. Bone Marrow Transplant. 1989 Sep;4(5):483–8.
Petersen, F. B., et al. “High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma.Bone Marrow Transplant, vol. 4, no. 5, Sept. 1989, pp. 483–88.
Petersen FB, Appelbaum FR, Bigelow CL, Buckner CD, Clift RA, Sanders JE, Storb R, Sullivan KM, Weiden PL, Fefer A. High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. Bone Marrow Transplant. 1989 Sep;4(5):483–488.

Published In

Bone Marrow Transplant

ISSN

0268-3369

Publication Date

September 1989

Volume

4

Issue

5

Start / End Page

483 / 488

Location

England

Related Subject Headings

  • Whole-Body Irradiation
  • Middle Aged
  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • Immunology
  • Humans
  • Hodgkin Disease
  • Cytarabine
  • Combined Modality Therapy
  • Clinical Trials as Topic